Valuation dashboard for Alterity Therapeutics Limited (ATHE) with P/E N/A, P/B 2.73, EV/EBITDA -3.58 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $3.85, ATHE has negative trailing earnings (P/E not meaningful) and an ROE of -53.57%. Market capitalisation stands at $65M.
Balance sheet quality for ATHE: current ratio of 14.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 2.73 |
| EV / EBITDA | -3.58 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $1.77 |
| vs Current Price | -54.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ATHE | Alterity Therapeutics Limited | $65M | 2.73 | -53.6% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $3.85 |
| Market Cap | $65M |
| Exchange | NASDAQ |
| Country | AU |
Profitability
| Return on Equity | -53.57% |
| Return on Invested Capital | -56.35% |
| Return on Assets | -49.74% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANVS · BTAI · DYAI · EVAX · GBIO · IGC · LIMN
Explore sector: Healthcare · Biotechnology
More sections of ATHE: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks